Sven Wehrwein, an insider at AtriCure Inc (ATRC), has acquired 39,407 shares of the company at a price of $19.95 per share, amounting to a total transaction value of $786,000. This purchase occurred on November 23, 2025, and brings Wehrwein's total holding in AtriCure to 39,407 shares.
AtriCure, headquartered in Mason, Ohio, focuses on the development, manufacture, and sale of surgical ablation systems for cardiac tissue, as well as products for managing the left atrial appendage. The company, which employs approximately 1,300 staff members, went public on August 5, 2005. Its product offerings include advanced devices for both open-heart and minimally invasive surgical procedures.
The move underscores the potential confidence insiders have in their company's future, as they typically possess insights not available to the public. However, it is important for investors to consider insider transactions as one of many data points in their decision-making process, rather than relying solely on individual trades.
AtriCure has a market capitalization of $1.6 billion and reported a trailing twelve months (TTM) earnings per share (EPS) of -0.62. Upcoming earnings are scheduled for April 27, 2026, with an estimated EPS of -0.11 and projected revenue of $141.4 million, followed by another report on July 27, 2026, with an estimated EPS of -0.04 and revenue of $155.3 million.